Table 4. ECG changes during treatment (baseline vs end of treatment), by treatment.

	Intraindividual changes at baseline	HAT Stage 1			HAT Stage 2
		DB289	Pentamidine	p-value	Melarsoprol	DFMO
	(N = 526)	(N = 229)	(N = 177)		(N = 47)	(N = 9)
Repolarisation changes (%)
appearance/aggravation	1.9	5.7	4.5	0.300	29.8	44.4
disappearance/improvement	1.5	13.1	9.6	0.138	12.8	11.1
Low voltage (%)
appearance	0.2	2.2	1.7	0.363	6.4	0
disappearance	0	1.3	1.7	0.625	4.3	0
AV block I (%)
appearance	1.3	2.6	1.1	0.190	0	0
disappearance	0.8	1.3	0.6	0.872	2.1	0